Literature DB >> 6771065

Inhibition of prolactin secretion by nomifensine in man.

A Masala, S Alagna, L Devilla, G Delitala, P P Rovasio.   

Abstract

Serum prolactin, TSH and GH levels were measured in thirty healthy volunteers in fasting conditions and following oral administration of 200 mg nomifensine. In addition, the effect of the drug on serum prolactin and TSH response to synthetic TRH was studied in twenty normal subjects. Inhibition of endogenous catecholamine reuptake by nomifensine significantly inhibited prolactin release whereas it had no effect on TSH and GH levels. Nomifensine administration had no appreciable effect on the TRH-induced release of TSH and prolactin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6771065     DOI: 10.1111/j.1365-2265.1980.tb02705.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

2.  Failure of nomifensine to reduce serum prolactin levels in patients with hepatic encephalopathy.

Authors:  A Masala; S Alagna; P P Rovasio; A Deplano; V Anania; L Chiandussi; M Langer
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

Review 3.  A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.

Authors:  R B Rothman; J R Glowa
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

4.  Nomifensine decreases the thyroid-stimulating-hormone response to thyrotropin-releasing-hormone in normal subjects.

Authors:  M Giusti; G Mazzocchi; D Mignone; W Tarditi; G Giordano
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.